



UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

| | |
|-------------------|---|
| Program Number | 2023 P 1324-4 |
| Program | Prior Authorization – Notification |
| Medication | Palforzia [Peanut (<i>Arachis hypogaea</i>) Allergen Powder-dnfp] |
| P&T Approval Date | 8/2020, 8/2021, 3/2022, 3/2023 |
| Effective Date | 6/1/2023; Oxford only: N/A |

1. Background:

Palforzia [Peanut (*Arachis hypogaea*) Allergen Powder-dnfp] is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Palforzia is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial dose escalation may be administered to patients aged 4 through 17 years. Up-dosing and maintenance may be continued in patients 4 years of age and older. Palforzia is to be used in conjunction with a peanut-avoidant diet.

2. Coverage Criteria^a:

A. Initial Authorization

1. **Palforzia** will be approved based on the following criteria:

a. Diagnosis of peanut allergy as documented by **both** of the following:

- (1) A serum peanut-specific IgE level of greater than or equal to 0.35 kUA/L
- (2) A mean wheal diameter that is at least 3mm larger than the negative control on skin-prick testing for peanut

- AND -

b. **One** of the following

(1) **Both** of the following

- (a) Patient is 4 to 17 years of age
- (b) Patient is in the initial dose escalation phase therapy

-OR-

(2) **Both** of the following:

- (a) Patient is 4 years of age and older
- (b) Patient is in the up-dosing or maintenance phase of therapy

-AND-



c. Used in conjunction with a peanut-avoidant diet

Authorization will be issued for 12 months.

B. Reauthorization

1. **Palforzia** will be approved based on the following criteria:

a. Documentation of positive clinical response to Palforzia therapy

-AND-

b. Used in conjunction with a peanut-avoidant diet

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Programs:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Prior Authorization-Medical Necessity may apply
- Supply limits may apply

4. References:

1. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for Peanut Allergy. *N Engl J Med.* 379(21):1991-2001.
2. Palforzia [prescribing information]. Brisbane, CA: Aimmune Therapeutics, Inc.; February 2020.

| Program | Prior Authorization – Notification – Palforzia |
|-----------------------|--|
| Change Control | |
| 8/2020 | New program. |
| 8/2021 | Annual review. No changes. |
| 3/2022 | No changes. |
| 3/2023 | Annual review. Added mandate language. |